Zelboraf (vemurafenib) / Roche 
Welcome,         Profile    Billing    Logout  
 50 Diseases   63 Trials   63 Trials   4298 News 


«12345678910111213...4950»
  • ||||||||||  Zelboraf (vemurafenib) / Roche
    Trial completion date:  AcS (clinicaltrials.gov) -  Dec 15, 2023   
    P2,  N=216, Active, not recruiting, 
    Cobimetinib plus vemurafenib showed antitumor activity in patients with advanced solid tumors with BRAF V600E mutations; additional study is warranted to confirm the antitumor activity in tumors with non-V600E BRAF mutations. Trial completion date: May 2024 --> Dec 2024
  • ||||||||||  Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Heterogeneity:  DARWIN II: Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (clinicaltrials.gov) -  Dec 4, 2023   
    P2,  N=50, Active, not recruiting, 
    Trial completion date: May 2024 --> Dec 2024 Recruiting --> Active, not recruiting | N=119 --> 50 | Trial completion date: Nov 2025 --> May 2026 | Trial primary completion date: Nov 2024 --> May 2026
  • ||||||||||  Tafinlar (dabrafenib) / Novartis, BeiGene, Zelboraf (vemurafenib) / Roche, Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal:  From a mutation to a drug (Pubmed Central) -  Dec 3, 2023   
    Then we provide information about other popular drugs for malignant melanoma, i.e. dacarbazine, ipilimumab and dabrafenib, and about the advantages of therapy with the simultaneous use of two inhibitors. Finally, we briefly discuss the role of artificial intelligence in the future of drug design.
  • ||||||||||  Tafinlar (dabrafenib) / Novartis, BeiGene, Zelboraf (vemurafenib) / Roche
    Review, Journal:  The Role of BRAF Inhibitors in the Management of Ameloblastoma: A Literature Review. (Pubmed Central) -  Nov 30, 2023   
    In the treatment of ameloblastomas, the identification of BRAF V600E and additional mutations as the prime targeted therapies has proven to be a significant breakthrough where surgical treatment was contraindicated. In this article, we review the presence of BRAF V600E mutations, their inhibitors, and targeted therapies in ameloblastoma.
  • ||||||||||  Zelboraf (vemurafenib) / Roche
    Preclinical, Journal:  Novel Anti-Melanoma Compounds Are Efficacious in A375 Cell Line Xenograft Melanoma Model in Nude Mice. (Pubmed Central) -  Nov 29, 2023   
    Animals were randomized into four groups (n = 12/group): 10 mg/kg vemurafenib, and 25 mg/kg 2155-14 and 2155-18 thrice a week for 15 days along with a control group...These results were confirmed by tumor volume, weight, and histopathological examination. In conclusion, these results demonstrate the therapeutic potential of targeting spliceosomal proteins hnRNPH1 and H2.
  • ||||||||||  Review, Journal:  Management of Brain Metastases: A Review of Novel Therapies. (Pubmed Central) -  Nov 28, 2023   
    Novel systemic therapies with intracranial utility include new anaplastic lymphoma kinase inhibitors like brigatinib and ensartinib; selective "rearranged during transfection" inhibitors like selpercatinib and pralsetinib; B-raf proto-oncogene inhibitors like encorafenib and vemurafenib; Kirsten rat sarcoma viral oncogene inhibitors like sotorasib and adagrasib; ROS1 gene rearrangement (ROS1) inhibitors, anti-neurotrophic tyrosine receptor kinase agents like larotrectinib and entrectinib; anti-human epidermal growth factor receptor 2/epidermal growth factor receptor exon 20 agent like poziotinib; and antibody-drug conjugates like trastuzumab-emtansine and trastuzumab-deruxtecan. This review highlights the modern multidisciplinary management of BM, emphasizing the integration of systemic and local therapies.
  • ||||||||||  Tafinlar (dabrafenib) / Novartis, BeiGene, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Zelboraf (vemurafenib) / Roche
    Review, Journal:  The Cytoprotective Role of Autophagy in Response to BRAF-Targeted Therapies. (Pubmed Central) -  Nov 3, 2023   
    Clinical trials have also demonstrated a potential benefit from the inclusion of autophagy inhibition as an adjuvant therapy. This review of the scientific literature relating to the role of autophagy that is induced in response to BRAF-inhibitors supports the premise that autophagy targeting or modulation could be an effective adjuvant therapy.
  • ||||||||||  Zelboraf (vemurafenib) / Roche
    Trial completion date, Trial primary completion date, Metastases:  Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer (clinicaltrials.gov) -  Nov 3, 2023   
    P2,  N=24, Active, not recruiting, 
    Vemurafenib plays an active role in targeted therapy. Trial completion date: Sep 2023 --> Sep 2026 | Trial primary completion date: Sep 2022 --> Sep 2026
  • ||||||||||  Tafinlar (dabrafenib) / Novartis, BeiGene, Zelboraf (vemurafenib) / Roche
    Long-Term Outcomes with Single-Agent BRAF-Inhibitor Therapy in Erdheim-Chester Disease (Halls G-H (San Diego Convention Center)) -  Nov 3, 2023 - Abstract #ASH2023ASH_6003;    
    P
    Our results also highlight the entity of disease progression on BRAFi therapy. Our results underscore the importance of developing therapies that are efficacious and well-tolerated in this incurable disease.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Zelboraf (vemurafenib) / Roche
    Serum Soluble Interleukin-2 Receptor Levels in Hairy Cell Leukemia As a Marker of Tumor Burden with Prognostic Value and As a Tool for Disease Monitoring (SDCC - Halls G-H) -  Nov 3, 2023 - Abstract #ASH2023ASH_5854;    
    Among treated patients, 47/54 (87%) received cladribine and 7/54 (13%) pentostatin...A similar decrease in sIL-2R levels after therapy was observed in 4 relapsed patients treated with rituximab-vemurafenib (median pre-therapy sIL-2R 11.460 vs. 467 kU/L after treatment, p = 0.03; median reduction 10.848 kU/L)...While more data is required to validate its use in clinical routine, sIL-2R could be used as an effective marker for disease monitoring. Moreover, given the prognostic significance of post-therapy levels, sIL-2R may represent a prognostic factor alongside MRD to identify those patients that are more likely to develop early relapse.
  • ||||||||||  Zelboraf (vemurafenib) / Roche
    Journal:  Antiproliferative Imidazo-Pyrazole-Based Hydrogel: A Promising Approach for the Development of New Treatments for PLX-Resistant Melanoma. (Pubmed Central) -  Oct 28, 2023   
    Aiming at developing a dermal formulation against melanoma, the synthesized imidazo-pyrazoles 2-phenyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazole-7-carboxylic acid (3-methoxy-4-phenoxy-benzylidene)-hydrazide (4G) and 2-phenyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazole-7-carboxylic acid (4-benzyloxy-3-methoxy-benzylidene)-hydrazide (4I) were screened on patient-isolated melanoma cells (MEOV NT) and on Vemurafenib (PLX4032)-resistant (MEOV PLX-R) ones...Release studies evidenced a sustained and quantitative release of 4I governed mainly by diffusion. Upon favorable results from further experiments in a more realistic 3D model of melanoma, R4HG-4I could represent a starting point to develop new topical therapeutic options to adjuvate the treatments of melanoma cells also when resistant to currently available drugs.
  • ||||||||||  Opdivo (nivolumab) / BMS, Braftovi (encorafenib) / Pfizer, Mektovi (binimetinib) / Pfizer
    Enrollment open, Trial primary completion date:  Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma (clinicaltrials.gov) -  Oct 19, 2023   
    P1,  N=13, Recruiting, 
    Upon favorable results from further experiments in a more realistic 3D model of melanoma, R4HG-4I could represent a starting point to develop new topical therapeutic options to adjuvate the treatments of melanoma cells also when resistant to currently available drugs. Active, not recruiting --> Recruiting | Trial primary completion date: May 2028 --> May 2024
  • ||||||||||  Zelboraf (vemurafenib) / Roche
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer (clinicaltrials.gov) -  Oct 19, 2023   
    P2,  N=12, Recruiting, 
    Active, not recruiting --> Recruiting | Trial primary completion date: May 2028 --> May 2024 Trial completion date: Sep 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Jun 2024
  • ||||||||||  Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Zelboraf (vemurafenib) / Roche, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
    COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma (Exhibition area) -  Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_1095;    
    P3
    After tx discontinuation, 15% of pts from the enco + bini arm, 42% from the vemu arm, and 28% from the enco alone arm received BRAF/MEKi tx; 42% from the enco + bini arm, 49% from the vemu arm, and 43% from the enco alone arm received checkpoint inhibitors. Conclusions With a median duration of follow-up of 100 mo, the 7-year analysis from COLUMBUS part 1 confirms the long-term, sustained efficacy and known safety profile of enco + bini, with no new safety signals emerging, in pts with BRAF V600
  • ||||||||||  Zelboraf (vemurafenib) / Roche
    Journal:  Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells. (Pubmed Central) -  Oct 4, 2023   
    We found that kisspeptin 54 increases vemurafenib pro-apoptotic activity in a statistically significant manner, also in drug resistant cellular models. The efficacy of the combination appears to reflect the intrinsic susceptibility of each cell line to PLX4032-induced apoptosis, together with the different mutational profile as well as perturbation of proteins regulating the apoptotic pathway, The results presented here highlight the possibility to exploit KiSS1 to modulate the apoptotic response to therapeutically relevant agents, suggesting a multitasking function of this metastasis suppressor.
  • ||||||||||  Trial completion date, Trial primary completion date, Tumor mutational burden:  The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (clinicaltrials.gov) -  Oct 3, 2023   
    P2,  N=400, Active, not recruiting, 
    The efficacy of the combination appears to reflect the intrinsic susceptibility of each cell line to PLX4032-induced apoptosis, together with the different mutational profile as well as perturbation of proteins regulating the apoptotic pathway, The results presented here highlight the possibility to exploit KiSS1 to modulate the apoptotic response to therapeutically relevant agents, suggesting a multitasking function of this metastasis suppressor. Trial completion date: Aug 2024 --> Jun 2025 | Trial primary completion date: Apr 2024 --> Dec 2024
  • ||||||||||  Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, XL888 / Exelixis, Merck (MSD)
    Journal, Metastases:  Combined BRAF, MEK, and heat-shock protein 90 (HSP90) inhibition in advanced BRAF V600-mutant melanoma. (Pubmed Central) -  Sep 30, 2023   
    Combined vemurafenib and cobimetinib plus XL888 had significant toxicity, requiring frequent dose reductions, which may have contributed to the relatively low progression-free survival despite a high tumor response rate. Given overlapping toxicities, caution must be used when combining HSP90 inhibitors with BRAF and MEK inhibitors.
  • ||||||||||  Zelboraf (vemurafenib) / Roche
    Review, Journal:  Fragment-based drug discovery successful contributions to current pharmacotherapeutic agents arsenal against aggressive cancers: A mini-review. (Pubmed Central) -  Sep 26, 2023   
    After a decade of approval of the drug vemurafenib in 2011, the hopeless scenario imposed by some severe cancer types has been mitigated by the magic bullets developed through fragment-based drug discovery...This mini-review highlights the successes achieved by these research campaigns in the fruitful field of the molecular fragment paradigm that resulted in the approval of six new anticancer drugs in the last decade (2011-2021), as well as several promising clinical candidates. It is a particularly encouraging opportunity for other researchers who want to become aware of the applicability and potency of this new paradigm applied to the design and development of powerful molecular weapons in the constant war against these merciless scourges of humanity.
  • ||||||||||  Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, Tecentriq (atezolizumab) / Roche
    Journal, PD(L)-1 Biomarker, IO biomarker:  Immune-Related Sclerosing Cholangitis and Subsequent Pyogenic Liver Abscesses in Two Patients With Melanoma Treated by Triplet Therapy: A Case Report. (Pubmed Central) -  Sep 20, 2023   
    To our knowledge, we report the first 2 cases of IR-cholangitis and subsequent liver abscesses without prior invasive intervention, the first cases of IR-cholangitis induced by triplet therapy, and 2 of the few anti-PD-L1 induced cases contributing to the evidence that both anti-PD1 and anti-PD-L1 antibodies induce IR-cholangitis. Treatment strategies for IR-cholangitis need to be improved to prevent life-threatening infectious complications.
  • ||||||||||  NN1213 / Novo Nordisk, Zelboraf (vemurafenib) / Roche
    Trial completion, Trial completion date, Metastases:  Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes (clinicaltrials.gov) -  Sep 8, 2023   
    P=N/A,  N=15, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2022 --> Dec 2023 Unknown status --> Completed | Trial completion date: Dec 2016 --> Jul 2023
  • ||||||||||  Zelboraf (vemurafenib) / Roche
    Preclinical, Journal:  Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro. (Pubmed Central) -  Aug 30, 2023   
    Importantly, ezrin inhibition potentiated anti-proliferative and pro-apoptotic effects of vemurafenib in the resistant melanoma cells in a synergistic manner. Altogether, our study suggests a role of ezrin in acquired resistance to vemurafenib in colon cancer and melanoma cells carrying the BRAFV600E mutation and supports further pre-clinical and clinical studies to explore the benefits of combined BRAF inhibitors and actin-targeting drugs as a potential therapeutic approach for BRAFV600E-mutated cancers.